Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Free Cash Flow (2016 - 2025)

Kiora Pharmaceuticals' Free Cash Flow history spans 11 years, with the latest figure at -$2.3 million for Q4 2025.

  • For Q4 2025, Free Cash Flow fell 2.32% year-over-year to -$2.3 million; the TTM value through Dec 2025 reached -$10.0 million, down 216.69%, while the annual FY2025 figure was -$10.1 million, 217.76% down from the prior year.
  • Free Cash Flow reached -$2.3 million in Q4 2025 per KPRX's latest filing, down from -$1.3 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $13.6 million in Q1 2024 to a low of -$3.8 million in Q2 2025.
  • Average Free Cash Flow over 5 years is -$1.4 million, with a median of -$2.6 million recorded in 2023.
  • Peak YoY movement for Free Cash Flow: skyrocketed 543.87% in 2024, then plummeted 238.42% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at -$2.9 million in 2021, then grew by 2.99% to -$2.8 million in 2022, then increased by 8.86% to -$2.6 million in 2023, then grew by 14.49% to -$2.2 million in 2024, then fell by 2.32% to -$2.3 million in 2025.
  • Per Business Quant, the three most recent readings for KPRX's Free Cash Flow are -$2.3 million (Q4 2025), -$1.3 million (Q3 2025), and -$3.8 million (Q2 2025).